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Instruments and Methods. Unless stated otherwise, chemicals were obtained from commercial
sources and used without any further purification. Peptide grade or pro analysi solvents were purchased
from Biosolve (Valkenswaard, the Netherlands) and dried on 4Å MS (MeOH: 3Å MS) before use. N,N-
Diisopropylethylamine (DIPEA) was distilled from ninhydrin and KOH-pellets. Rf values were
determined by thin layer chromatography (TLC) on Merck precoated silicagel 60F254 plates. Spots were
visualized with UV quenching, ninhydrin or with Cl2-TDM.
1 Solid phase peptide synthesis was
monitored with the Kaiser test2 and the loading of the resin3 was determined using a Heλios β UV/VIS-
spectrophotometer at λ 300 nm. Solvents were removed by rotary evaporation under reduced pressure
at 40 °C. Melting points were determined using a Büchi melting point apparatus accordig to dr. Tottoli
and were uncorrected. 1H NMR (300 MHz) and 13C NMR (75 MHz) spectra were measured on a
Varian G-300 spectrometer. 1H NMR 500 MHz spectra were recorded on a Varian INOVA-500
spectrometer. 1H NMR chemical shifts are given in ppm (δ) relative to TMS and 13C NMR chemical
shifts are given in ppm (δ) relative to CDCl3 (77.0 ppm). 
13C NMR spectra were recorded using the
attached proton test (APT) pulse sequence. Analytical HPLC runs were performed on a Shimadzu
automated HPLC (SPD-10A VP) system equipped with an evaporative light scattering detector (PL-
ELS 1000, Polymer Laboratories) and a UV/VIS detector operating at 220/254 nm. Preparative HPLC
runs were performed on a Gilson HPLC workstation. Chiral HPLC analysis was performed on an
analytical reverse-phase column (Astec, Teicoplanin, Chirobiotic T, 250 × 4.6 mm) at a steady flow of
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0.5 mL/min  with 1% TEA in H2O adjusted to pH 4 with AcOH/MeOH 1:1 v/v as eluens. Electrospray
ionisation (ESI) mass spectrometry was carried out on a Shimadzu LCMS QP-8000 quadrupole
benchtop spectrometer coupled to a QP-8000 data system. MS/MS-spectra were measured on a
Micromass Quattro Ultima or a Micromass Q-TOF mass spectrometer.Optical rotations were measured
on a Jasco P-1010 Polarimeter.
Solid phase peptide synthesis: Peptides 14 and 16 were synthesized manually on a 0.25 mmol scale
on plain Argogel resin. Each synthetic cycle consisted of N-α-Fmoc removal by treatment with 20%
piperidine in DMF (3 × 10 mL, 8 min), a washing step (DMF: 3 × 10 mL, 2 min; DCM: 3 × 10 mL, 2
min and DMF: 3 × 10 mL, 2 min) a coupling step (60 min) with 1.0 mmol of preactivated Fmoc amino
acid in the presence of 2 equivalents DIPEA in DMF (10 mL) and a final washing step (DMF: 3 × 10
mL, 2 min; DCM: 3 × 10 mL, 2 min and DMF: 3 × 10 mL, 2 min). N-α-Fmoc amino acids (1 mmol)
were activated in situ with BOP (1 mmol) in the presence of DIPEA (2 mmol). Fmoc-removal and
coupling reactions were monitored by the Kaiser test.2 The peptides were cleaved from the resin by
treatment with a catalytic amount of KCN in MeOH (15 mL) during 16 h. The resin was filtered and
washed with MeOH (3 × 10 mL), the filtrate was concentrated in vacuo to yield the crude peptide.
Solution phase peptide synthesis: Coupling reaction: The carboxylic acid moiety (1 equiv) was
coupled to the amine derivative (or its TFA-salt, 1 equiv) in the presence of BOP (1 equiv) and DIPEA
(2 equiv, when the amine was protonated 3 equiv were used) as coupling reagents in DCM (10 mL per
mmol) as solvent. Coupling time was 16 h. After completion of the reaction, DCM was removed under
reduced pressure and the residue was dissolved in EtOAc (25 mL per mmol). The EtOAc solution was
washed with 1N KHSO4 (3 × 25 mL), 10% Na2CO3 (3 × 25 mL) and brine (1 × 25 mL), dried
(Na2SO4), filtrated and evaporated in vacuo. The obtained crude product was analyzed by TLC, 
1H
NMR and ESI-MS and generally pure enough to be used in the next synthesis steps.
Boc-removal: A Boc-protected intermediate was dissolved in TFA/DCM 1:1 v/v (4 mL per mmol) and
stirred for 2 h. Then, the solvents were removed under reduced pressure and the residue was
coevaporated with toluene (2 × 25 mL), CH3CN (2 × 25 mL) and DCM (2 × 25 mL) to remove any
residual TFA. The obtained TFA-salt was used without further purification in the next synthesis steps.
Peptide purification: The crude lyophilized peptides (30-60 mg) were dissolved in a minimum amount
of 0.1% TFA in CH3CN/H2O 8:2 v/v and loaded onto an Adsorbosphere XL C8 HPLC column (90Å
pore size, 10 µm particle size, 25 × 2.2 cm). The peptides were eluted with a flow rate of 10.0 mL/min
using a linear gradient of buffer B (100% in 60 min) from 100% buffer A (buffer A: 0.1% TFA in H2O,
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buffer B: 0.1% TFA in CH3CN/H2O 95:5 v/v). The purities were evaluated by analytical HPLC on an
Adsorbosphere XL C8 column (90Å pore size, 5 µm particle size, 25 × 0.46 cm) at a flow rate of 1
mL/min using a linear gradient of buffer B (100% in 30 min) from 100% buffer A (buffer A: 0.1% TFA
in H2O; buffer B: 0.1% TFA in CH3CN/H2O 95:5 v/v).
Peptide characterization: The peptides were characterized by mass spectrometry and 1H NMR (300
or 500 MHz). The mass of each analog was measured and the observed monoisotopic (M + H)+ values
were correlated with the calculated (M + H)+ values using MacBioSpec (Perkin Elmer Sciex
Instruments, Thornhill, Ontario, Canada). Peak assingments were based on 1H NMR COSY, TOCSY
and/or ROESY spectra.
General procedure of ring closing alkyne metathesis (RCAM). All RCAM reactions were carried
out under argon in flame-dried glassware using Schlenk techniques. A solution of the peptide and the
catalyst ((tBuO)3W≡CCMe3) in toluene stirred at 80 
oC till TLC analysis showed the completion of the
reaction. Water (1 mL) was added to the reaction mixture and stirred for 10 min to quench the catalyst.
After the evaporation of the solvent the product was purified by column chromatography.
Alkylation of the Gly/Ni/BPB-complex with 1-Bromo-2-butyne: The Gly/Ni/BPB-complex4,5 (6 g,
12 mmol) and NaOH (1.2 g, 30 mmol) were dissolved in CH3CN (60 mL) and 1-bromo-2-butyne (1.2
mL, 13.4 mmol) was added dropwise. The deeply red mixture was stirred for 1.5 h at room
temperature. Then, the excess of NaOH was neutralized with HCl (0.1 M, 180 mL). The alkylation
product was extracted into CH2Cl2. The combined organic layers were dried (MgSO4) and evaporated
to dryness. The product was purified by silicagel column chromatography (eluens CHCl3/acetone 5:1
v/v) to obtain both diastereoisomers as red crystals with 61% yield (4 g). Rf: 0.55 (CH2Cl2/acetone 2:1
v/v). [α]D
21 +268 (c 0.1 MeOH). 1H NMR (300 MHz, CDCl3) δ: 1.93-2.01 (s, 3H, _H-Bug); 2.02-2.18
(m, 2H, _Pro); 2.21-2.35 (m, 1H, βH-Bug); 2.44-2.68 (m, 2H, [1H, (βH-Bug), 1H, (γH-Pro)]; 2.72-2.94
(m, 1H, γH-Pro); 3.41-3.50 (m, 1H, δH-Pro); 3.51-3.61 (m, 1H, δH-Pro); 3.61-3.82 (m, 2H, [1H, d,
(CH2-Ph), 1H, m, (αH-Pro)]; 3.96-4.04 (q, 1H, αH-Bug); 4.42-4.52 (d, 1H, CH2-Ph); 6.61-8.24 (m,
14H, Ar-H). 13C NMR (75 MHz, CDCl3) δ: 4.1 (εC-Bug); 23.0 (γC-Pro); 23.9 (βC-Pro); 30.6 (βC-
Bug); 56.4 (δC-Pro); 62.8 (Ph-CH2-N); 68.1 (αC-Bug); 70.0 (αC-Pro); 73.8 (γC-Pro); 80.4 (δC-Pro);
120.6, 123.6, 126.5, 127.7, 128.8, 129.0, 129.7, 131.5, 132.3, 133.4 (Ar-CH); 126.3, 133.0, 133.9,
142.5 (Ar-C); 171.5 (C=N); 178.8 (C=O, Pro); 180.2 (C=O, Gly). ESI-MS: m/z 550.45 [M+H]+,
(C31H29N3NiO3: M: 549.16).
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(S)-2-amino-5-hexynoic acid (H-Bug-OH) 1: The alkylated nickel-complex (10.1 g, 18.4 mmol) was
dissolved in MeOH (300 mL) and heated till reflux. To this solution 2N HCl (200 mL) was added and
the reaction mixture was refluxed. After 45 min the solvents were evaporated in vacuo. The green solid
was dissolved in H2O and neutralized with concentrated ammonia until pH 9 was reached and
subsequently concentrated to dryness. The obtained solid was washed with acetone to recover the chiral
auxillary (5.8 g, 82%). After that, the remaining solid was suspended in H2O and centrifuged, the pellet
was resuspended once and the insoluble material was collected by centrifugation. The obtained pellet
was dried overnight in a vacuum dessicator to give 4.1 g of crude amino acid 1. The combined aqueous
layers were evaporated to dryness and the residue was treated with a cation exchange resin (Dowex
50X8 H+ form) to obtain the pure amino acid (301 mg, 13%). The crude product was purified by
reaction with (Boc)2O to give the Boc-protected amino acid (2.83 g, 12.4 mmol, 67%) after treatment
with HCl in diethyl ether the hydrochloride of 1 was obtained (2.06 g, 12.4 mmol). R f: 0.1
(CHCl3/MeOH/HOAc 95:20:3 v/v/v). [α]D
21 -7.8 (c 1.22 MeOH). 1H NMR (300 MHz, CD3OD) δ:
3.77-3.80 (m, 1H, αH); 2.50-2.53 (m, 2H, βH); 1.45-1.46 (t, 3H, εH). 13C NMR (75 MHz, CD3OD) δ(:
170.4 (C=O); 82.2 (γC); 71.7(δC); 52.9 (αC); 21.6 (βC); 3.2 (εC).
(S)-N-(9-fluorenylmethyloxycarbonyl)-2-amino-5-hexynoic acid (Fmoc-Bug-OH) 4: HCl.H-Bug-
OH 1 (0.83 mmol) was dissolved in H2O (5 mL) and the pH was set to 9 with TEA. Fmoc-ONSu (269
mg, 0.8 mmol) was dissolved in CH3CN (5 mL) and added to the basic solution. The reaction mixture
was stirred at room temperature and the pH was kept at pH 8-8.5 with TEA. After 1.5 h the reaction
was complete and CH3CN was evaporated in vacuo. The mixture was acidified with 1N KHSO4 to pH
1-2 and extracted with EtOAc. The organic layer was dried with Na2SO4 and evaporated. The crude
product was purified by silicagel column chromatography (eluens: CH2Cl2/MeOH 98:2 → 90:10 v/v) to
give 4 (221 mg, 75%) as a white solid. Rf: 0.51 (CHCl3/MeOH/HOAc 95:20:3 v/v/v). [α]D
21 -17 (c 0.95
DMF). 1H NMR (300 MHz, CDCl3/CD3OD 9:1 v/v) δ: 1.71-1.82 (s, 3H, εH-Bug); 2.63-2.88 (m, 2H,
βH-Bug); 4.21-4.32 (t, 1H, CH-Fmoc); 4.40-4.48 (d, 2H, CH2-Fmoc); 4.48-4.60 (m, 1H, αH-Bug);
7.22-7.82 (m, 8H, Ar-Fmoc). 13C NMR (75 MHz, CDCl3/CD3OD 9:1 v/v) δ: 172.5 (C=O, Bug); 156.0
(C=O, Fmoc), 143.5, 141.0, 127.5, 126.9, 124.9, 119.7 (Arom C, Fmoc); 78.8 (γC, Bug); 72.9 (δC,
Bug); 66.9 (CH2, Fmoc); 52.4 (αC, Bug); 46.8 (CH, Fmoc); 22.5 (βC, Bug); 3.1 (εC, Bug).
(RS)-N-(9-fluorenylmethyloxycarbonyl)-2-amino-5-hexynoic acid (Fmoc-Bug-OH) rac-4: To a
suspension of K2CO3 (836 mg, 6.03 mmol) in CH3CN (10 mL), tetrabutylammonium bromide (21 mg,
0.01 eq) followed by methyl N-(diphenylmethy1ene)-glycinate6,7 (508 mg, 2 mmol) were added. After
stirring for 20 min, 1-bromo-2-butyne (186 _L, 2 mmol, 1 eq) was added dropwise and the reaction
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mixture was refluxed overnight. After filtration and extensively washing of the remaining solids with
diethyl ether, the organic layer was concentrated in vacuo. The product was redissolved in diethyl ether,
and the organic phase was washed with H2O (2 × 25 mL). The organic layer was dried (MgSO4) and
evaporated to dryness. After purification by column chromatography using basic alumina (eluens:
EtOAc/hexanes 9:1 v/v) the alkylation product was obtained in 61% (372 mg). The imine was
dissolved in diethyl ether (10 mL) and treated with 1M HCl (2.5 mL) for 3 h. The organic phase was
separated and subsequently washed with H2O. The HCl solution and the combined H2O washings were
concentrated to dryness and the residue was crystallized from MeOH/EtOAc to give 170 mg (84%) of
racemic HCl.H-Bug-OH. Fmoc protection of the amino group was carried out as described for 4, yield:
71%.
Boc-Bug-Ile-Ala-Leu-Bug-OMe 6: Coupling and Boc-removal were carried out as described in the
general procedure solution phase peptide synthesis.
HCl.H-Bug-OMe 2: To a solution of HCl.H-Bug-OH (337 mg, 2 mmol) in MeOH (10 mL) was added
dropwise SOCl2 (362 _L, 5 mmol) at 0 
oC. After 5 minutes of stirring the reaction mixture refluxed for
3 h. The methyl ester 2 was obtained after concentration in vacuo and coevaporation with CH3CN and
CHCl3 in quantitative yield. Rf: 0.40 (CHCl3/MeOH/HOAc 95:20:3 v/v/v). 
1H NMR (300 MHz,
CD3OD) δ: 4.11-4.14 (m, 1H, αH); 3.75 (s, OCH3); 2.74-2.77 (m, 2H, βH); 1.67-1.70 (t, 3H, εH). 
13C
NMR (75 MHz, CD3OD) δ: 169.6 (C=O); 82.4 (γC); 71.5(δC); 53.9 (αC); 53.0 (OCH3); 21.6 (βC); 3.2
(εC).
Boc-Leu-Bug-OMe: Yield: 91%. Rf(DCM/MeOH 9:1 v/v): 0.84; 
1H NMR (CDCl3, 300 MHz) Leu: _
5.39 (d, 1H, NH), 4.24 (m, 1H, C_H), 1.51-1.70 (m, 3H, C_H/CγH), 1.45 (s, 9H, Boc), 0.93-0.97 (m,
6H, C_H); Bug: _ 7.09 (d, 1H, NH), 4.64 (m, 1H, C_H), 3.77 (s, 3H, OCH3), 2.67 (m, 2H, C_H), 1.76
(t, 3H, C_H); ES-MS: calcd for C18H31N2O5: 355.2, found: m/z: [M + Na]
+ 377.4, [(M – C5H8O2) + H]
+
255.3.
Boc-Ala-Leu-Bug-OMe: Yield: 93%. Rf(DCM/MeOH 9:1 v/v): 0.68; 
1H NMR (CDCl3, 300 MHz) Ala:
_ 5.54 (d, 1H, NH), 4.33 (m, 1H, C_H), 1.44 (s, 9H, Boc), 1.34 (d, 3H, C_H); Leu: _ 7.19 (d, 1H, NH),
4.58 (m, 1H, C_H), 1.49-1.70 (m, 3H, C_H/CγH), 0.91-0.95 (m, 6H, C_H); Bug: _ 7.19 (d, 1H, NH),
4.63 (m, 1H, C_H), 3.77 (s, 3H, OCH3), 2.49-2.64 (m, 2H, C_H), 1.74 (s, 3H, C_H); ES-MS: calcd for
C21H36N3O6: 426.3, found: m/z: [M + H]
+ 426.6, [M + Na]+ 448.4, [(M – C4H8) + H]
+ 370.3, [(M –
C5H8O2) + H]
+ 326.3.
Boc-Ile-Ala-Leu-Bug-OMe: Coupling of Boc-Ile-OH with TFA.H-Ala-Leu-Bug-OMe was carried out
in DMF. The tetrapeptide was isolated by trituration with EtOAc. Yield: 87%. Rf(DCM/MeOH 9:1
v/v): 0.62; 1H NMR (CDCl3, 300 MHz) Ile: _ 5.75 (d, 1H, NH), 4.20 (m, 1H, C_H), 1.80 (m, 1H,
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C_H), 1.77 (m, 1H, CγH), 1.54 (m, 1H, CγH), 1.43 (s, 9H, Boc), 0.85-0.91 (m, 6H, Cγ’H/C_H); Ala: _
7.79 (d, 1H, NH), 4.72 (m, 1H, C_H), 1.35 (d, 3H, C_H); Leu: _ 7.66 (d, 1H, NH), 4.72 (m, 1H, C_H),
1.60-1.70 (m, 2H, C_H), 1.04 (m, 1H, CγH), 0.85-0.91 (m, 6H, C_H); Bug: _ 7.57 (d, 1H, NH), 5.74
(m, 1H, CγH), 5.01 (m, 2H, C_H), 4.72 (m, 1H, C_H), 3.74 (s, 3H, OCH3), 2.49-2.56 (m, 2H, C_H);
1.74 (s, 3H, C_H); ES-MS: calcd for C27H47N4O7: 539.3, found: m/z: [M + H]
+ 539.6, [M + Na]+ 561.6,
[(M – C4H8) + H]
+ 438.5, [(M – C5H8O2) + H]
+ 439.5.
Boc-Bug1-Ile2-Ala3-Leu4-Bug5-OMe (6): Coupling of Boc-Bug-OH with TFA.H-Ile-Ala-Leu-Bug-OMe
was carried out in DCM. The pentapeptide was isolated by trituration with EtOAc. Yield: 350 mg (73%
over 7 steps); Rt: 17.6 min; Rf(DCM/MeOH 9:1 v/v): 0.60; 
1H NMR (CDCl3/CD3OH 14.5:1 v/v, 500
MHz) Bug1: _ 5.72 (br s, 1H, NH), 4.14 (m, 1H, C_H), 2.54 (m, 2H, C_H), 1.74 (s, 3H, C_H); 1.47 (s,
9H, Boc); Ile2: _ 7.18 (d, 1H, NH), 4.28 (m, 1H, C_H), 1.93 (m, 1H, CγH), 1.54 (m, 1H, CγH), 1.06 (m,
1H, C_H), 0.90 (m, 6H, Cγ’H/C_H); Ala3: _ 7.57 (br s, 1H, NH), 4.44 (m, 1H, C_H), 1.40 (d, 3H,
C_H); Leu4: _ 7.44 (d, 1H, NH), 4.46 (m, 1H, C_H), 1.78 (m, 1H, CγH), 1.60 (m, 2H, C_H), 0.90 (m,
6H, C_H); Bug5: _ 7.36 (d, 1H, NH), 4.59 (m, 1H, C_H), 3.76 (s, 3H, OCH3), 2.54 (m, 2H, C_H), 1.78
(s, 3H, C_H); ES-MS: calcd for C33H54N5O8: 648.4, found: m/z: [M + H]
+ 648.7, [M + Na]+ 670.6, [(M
– C4H8) + H]
+ 592.6, [(M – C5H8O2) + H]
+ 548.9.
Boc-cyclo[Bug1-Ile2-Ala3-Leu4-Bug5]-OMe 7: Linear pentapeptide 6 (45.9 mg, 0.07 mmol) was
dissolved in toluene (200 mL) and the catalyst (4.4 mg, 9.3 _mol) was added. The obtained mixture
was heated to and stirred at 80 oC for two h. The product was purified by column chromatography
(DCM/MeOH 97.5:2.5 v/v). Yield: 17.8 mg (42%); Rt: 16.4 min; Rf(DCM/MeOH 9:1 v/v): 0.56 ; 
1H
NMR (CDCl3/CD3OH 14.5:1 v/v, 500 MHz) Bug
1: _ 5.84 (d, 1H, NH), 4.27 (m, 1H, C_H), 2.67 (m,
2H, C_H), 1.45 (s, 9H, Boc); Ile2: _ 7.42 (m, 1H, NH), 4.18 (m, 1H, C_H), 1.91 (m, 1H, CγH), 1.58 (m,
1H, CγH), 1.06 (m, 1H, C_H), 0.92 (m, 6H, Cγ’H/C_H); Ala3: _ 7.72 (br s, 1H, NH), 4.09 (m, 1H,
C_H), 1.51 (d, 3H, C_H); Leu4: _ 7.98 (d, 1H, NH), 4.18 (m, 1H, C_H), 1.81 (m, 1H, CγH), 1.62 (m,
2H, C_H), 0.92 (m, 6H, C_H); Bug5: _ 7.42 (m, 1H, NH), 4.60 (m, 1H, C_H), 3.79 (s, 3H, OCH3), 2.67
(m, 2H, C_H). ES-MS: calcd for C29H48N5O8: 594.4, found: m/z: [M + H]
+ 594.7, [M + Na]+ 617.5,
[(M – C4H8) + H]
+ 538.6, [(M – C5H8O2) + H]
+ 494.5. HRMS: calcd for C29H47N5O8Na: 616.33218.
Found: 616.33223.
Boc-Bug-Pro-Gly-OMe 8: Boc-Pro-OH (495 mg, 2.3 mmol) and HCl.H-Gly-OMe (300 mg, 2.4
mmol) were coupled in the presence of BOP (1.02 g, 2.3 mmol) and DIPEA (962 _L) in DCM (25 mL)
as described in the general procedure solution phase peptide synthesis.
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Boc-Pro-Gly-OMe: Yield: 592 mg (90%); Rf(DCM/MeOH 9:1 v/v): 0.48; 
1H NMR (CDCl3, 300 MHz)
Pro: δ 4.31 (m, 1H, C_H), 3.49 (m, 2H, C_H), 2.14-2.20 (m, 2H, C_H), 1.86-1.98 (m, 2H, CγH), 1.46
(s, 9H, Boc); Gly: _ 7.01 and 7.39 (m, 1H, NH), 4.04 (m, 2H, C_H), 3.74 (s, 3H, OCH3). ); ES-MS:
calcd for C13H22N2O5Na: 309.1, found: m/z: [M + Na]
+ 309.2, [M + Na + ACN]+ 350.2,[(M – C4H8) +
H]+ 228.1, [(M – C5H8O2) + H]
+ 187.1.
The protected dipeptide (300 mg, 1.1 mmol) was treated with TFA/DCM 1:1 v/v (4 mL) for 2 h to
remove the Boc group. Then, the reaction mixture was concentrated in vacuo and coevaporated with
toluene (2 × 10 mL), CH3CN (2 × 10 mL) and DCM (2 × 10 mL) to remove any residual TFA. The
TFA-salt was dissolved in DCM (15 mL) and to this solution were added: Boc-Bug-OH (228 mg, 1.0
mmol), BOP (442 mg, 1.0 mmol) and DiPEA (436 µL, 2.5 mmol) and the obtained reaction mixture
was stirred overnight. After evaporation of DCM, the residue was dissolved in EtOAc (50 mL) and this
solution was washed with 1N KHSO4 (3 × 20 mL), 10% Na2CO3 (3 × 20 mL) and brine (1 × 20 mL),
dried (Na2SO4), filtrated and evaporated in vacuo.
Boc-Bug-Pro-Gly-OMe 8: was obtained in 75% yield (297 mg) after column chromatography
(DCM/MeOH 97.5/2.5 v/v). Rf(DCM/MeOH 9:1 v/v): 0.60; 
1H NMR (CDCl3, 300 MHz) Bug: δ 5.51
(d, 1H, NH), 4.60 (m, 1H, C_H), 2.51 (m, 2H, C_H), 1.74 (s, 3H, C_H), 1.44 (s, 9H, Boc); Pro: δ 4.69
(m, 1H, C_H), 3.66 (m, 2H, C_H), 2.35 (m, 2H, C_H), 2.04 (m, 2H, CγH); Gly: _ 7.33, 7.97 (m, 1H,
NH), 3.95 (2xd, 2H, C_H), 3.73 (s, 3H, OCH3); ES-MS: calcd for C28H32N3O6: 506.2, found: m/z: [M +
Na]+ 418.35,[(M – C4H8) + H]
+ 340.3, [(M – C5H8O2) + H]
+ 296.2.
Boc-Bug1-Pro2-Gly3-Bug4-OMe 9: Boc-Bug-Pro-Gly-OMe 8 (240 mg, 0.6 mmol) was dissolved in
THF (10 mL) and the methyl ester saponified with 0.2N LiOH (5 mL) during 2 h. Then, THF was
removed in vacuo and the aqueous solution was acidified with 1N KHSO4 and subsequently extracted
with EtOAc (3 × 20 mL). The combined EtOAc layers were washed with brine (1 × 15 mL), dried
(Na2SO4), filtered and concentrated in vacuo. Boc-Bug-Pro-Gly-OH was obtained in quantitative yield
(214 mg) and was used in the next step without further purification. HCl.H-Bug-OMe (130 mg, 0.7
mmol) was dissolved in DCM (10 mL) and the tripeptide acid was added followed by BOP (265 mg,
0.6 mmol) and DIPEA (305 µL, 1.75 mmol) and the mixture was stirred overnight. The reaction
mixture was concentrated in vacuo and the residue was dissolved in EtOAc (20 mL) and this solution
was washed with 1N KHSO4 (3 × 5 mL), 10% Na2CO3 (3 ×  5 mL) and brine (1 × 5 mL), dried
(Na2SO4), filtrated and evaporated in vacuo. Tetrapeptide 9 was purified by column chromatography
(DCM/MeOH 97.5:2.5) and obtained in 86% yield (260 mg). Rt:15.3 min; Rf(DCM/MeOH 9:1 v/v):
0.56. 1H NMR (CDCl3, 500 MHz); Bug
1: 5.42 and 5.47 (2 × d, 1H, NH), 4.63 (m, 1H, C_H), 2.54-2.67
(m, 2H, C_H), 1.42 (s, 9H, Boc); Pro2: 4.63 (m, 1H, C_H), 3.88 (m, 2H, C_H), 2.29 (m, 2H, C_H),
S8
2.06 (m, 2H, CγH); Gly3: _ 7.31 and 8.80 (s, 1H, NH), 3.93-4.05 (m, 2H, C_H); Bug4: _ 7.21 and 6.96
(d, 1H, NH), 4.63 (m, 1H, C_H), 3.78 (s, 3H, OCH3), 2.46-2.63 (m, 2H, C_H), 1.79 (s, 3H, CεH). ES-
MS: calcd for C25H37N4O7: 505.6 found: m/z: [M + H]
+ 505.4, [M + Na]+ 527.5, [(M – C4H8) + H]
+
449.5, [(M – C5H8O2) + H]
+ 406.45.
Boc-cyclo[Bug1-Pro2-Gly3-Bug4]-OMe 10: Ring-closure was carried according the general procedure
with 8% catalyst at the concentration of 2 mM in toluene. Cyclic pentapeptide 10 was purified by
column chromatography (DCM/MeOH 97.5:2.5 v/v) and was obtained as a white powder in 82% yield
(83.2 mg). Rt:14.0 min; Rf(DCM/MeOH 9:1 v/v): 0.43; 
1H NMR (CDCl3, 500 MHz); Bug
1: 5.89 (d,
1H, NH), 4.66 (m, 1H, C_H), 2.47-2.60 (m, 2H, C_H), 1.50 (s, 9H, Boc); Pro2: 4.40 (m, 1H, C_H),
3.59 (m, 2H, C_H), 1.96-2.37 (m, 4H, C_H + CγH), Gly3: _ 7.21 (s, 1H, NH), 3.62-4.40 (dd, 2H, C_H);
Bug4: _ 8.03 (d, 1H, NH), 4.90 (m, 1H, C_H), 3.89 (s, 3H, OCH3), 2.60-2.78 (m, 2H, C_H). ES-MS:
calcd for C21H31N4O7: 551.5 found: m/z: [M + H]
+ 451.6, [M + Na]+ 473.5, [(M – C4H8) + H]
+ 395.3,
[(M – C5H8O2) + H]
+ 351.3. HRMS: calcd for C21H30N4O7Na: 473.20096. Found: 473.20122.
Boc-Ala-D-Leu-Nle-Gly-Bug-OMe 11: To a solution of Boc-Ala-D-Leu-Nle-Gly-OH (236 mg, 0.5
mmol) in DCM (10 mL), HOBt.H2O (100 mg, 0.6 mmol) and HCl.H-Bug-OMe (116 mg, 0.6 mmol)
were added followed by DIPEA (223 µL). The mixture was cooled to –15oC and EDCI (124.6 mg, 0.6
mmol) was added. The obtained reaction mixture was stirred overnight. Then, the reaction mixture was
worked up using the standard procedures as described above. Yield after column purification (eluens:
DCM/MeOH 95:5 v/v) was 246 mg (82%); Rf(DCM/MeOH 9:1 v/v): 0.36; 
1H NMR (CDCl3, 300
MHz) Ala: _ 5.91 (d, 1H, NH), 4.34 (m, 1H, C_H), 1.41 (s, 9H, Boc), 1.35 (d, 3H, C_H); D-Leu: _ 7.76
(d, 1H, NH), 4.90 (m, 1H, C_H), 1.83 (m, 1H, CγH), 1.63 (m, 2H, C_H), 0.89-0.95 (m, 6H, C_H); Nle:
_ 8.16 (br s, 1H, NH), 4.90 (m, 1H, C_H), 1.63 (m, 2H, C_H), 1.42-1.47 (m, 2H, CγH), 1.26-1.37 (m,
2H, C_H), 0.89-0.95 (m, 3H, C_H); Gly: _ 8.09 (m, 1H, NH), 4.12-4.39 (dd, 2H, C_H); Bug: _ 8.00 (d,
1H, NH), 4.71 (m, 1H, C_H), 3.77 (s, 3H, OCH3), 2.67 (m, 2H, C_H), 1.74 (s, 3H, C_H). ES-MS: calcd
for C29H50N5O8: 596.4, found: m/z: [M + Na]
+ 618.6.
Boc-Bug1-Gly2-Ala3-D-Leu4-Nle5-Gly6-Bug7-OMe 12: Pentapeptide 11 (240 mg, 0.4 mmol) was
dissolved in TFA/DCM 1:1 v/v (4 mL) to remove the Boc group and worked up as described. The
obtained TFA-salt was dissolved in DCM (10 mL) and to this solution, Boc-Bug-Gly-OH (141 mg, 0.5
mmol) and HOBt.H2O (76.7 mg, 0.5 mmol) were added. The obtained mixture was cooled to -15
oC and
EDCI (97 mg, 0.5 mmol) followed by DiPEA (105 µL, 0.6 mmol) were added. After stirring for 16 h,
DCM was removed under reduced pressure and 12 was purified by trituration with EtOAc. Yield: 191
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mg (63 %); Rf(DCM/MeOH 9:1 v/v): 0.46; Rt: 16.6 min; 
1H NMR (CDCl3/CD3OH 14.5:1 v/v, 500
MHz) Bug1: _ 5.75 (d, 1H, NH), 4.17 (m, 1H, C_H), 2.61-2.67 (m, 2H, C_H), 1.78 (s, 3H, C_H), 1.45
(s, 9H, Boc); Gly2/6: _ 7.90/7.63 (m, 1H, NH), 4.08/3.71 (2 × dd, 2H, C_H); Ala3: _ 7.66 (m, 1H, NH),
4.34 (m, 1H, C_H), 1.36 (d, 3H, C_H); D-Leu4: _ 7.66 (d, 1H, NH), 4.34 (m, 1H, C_H), 1.90 (m, 2H,
C_H), 1.65 (m, 1H, CγH), 0.89 (m, 6H, C_H); Nle5: _ 7.69 (d, 1H, NH), 4.34 (m, 1H, C_H), 1.90 (m,
2H, C_H), 1.56 (m, 2H, CγH), 1.32 (m, 2H, C_H), 0.89 (m, 3H, C_H); Bug7: _ 7.49 (m, 1H, NH), 4.61
(m, 1H, C_H), 3.76 (s, 3H, OCH3), 2.61-2.67 (m, 2H, C_H), 1.78 (s, 3H, C_H); ES-MS: calcd for
C37H60N7O10: 762.9, found: m/z: [M + H]
+ 762.6, [M + Na]+ 784.7, [(M – C4H8) + H]
+ 706.8, [(M –
C5H8O2) + H]
+ 662.6.
Boc-cyclo[Bug1-Gly2-Ala3-D-Leu4-Nle5-Gly6-Bug7]-OMe 13: To a solution of the fully protected
linear heptapeptide 12 (21.6 mg, 0.028 mmol) in toluene, 3.6 mg of catalyst was added and the mixture
was stirred for 3 h at 80oC. After concentrating in vacuo, the cyclic product was purified by column
chromatography (DCM/MeOH 97.5:2.5 v/v). Yield: 3.6 mg (18%); Rf(DCM/MeOH 97.5:2.5 v/v) 0.42;
Rt 15.5 min; 
1H NMR (CDCl3/CD3OH 14.5:1 v/v, 500 MHz) Bug
1: _ 6.03 (bs, 1H, NH), 4.34 (m, 1H,
C_H), 2.62-2.85 (m, 2H, C_H), 1.46 (s, 9H, Boc); Gly2: _ 8.16 (bs, 1H, NH), 3.95 (m, 2H, C_H); Ala3;
_ 7.49 (m, 1H, NH), 4.34 (m, 1H, C_H), 1.35 (d, 3H, C_H); D-Leu4: _ 7.74 (br s, 1H, NH), 4.34 (m,
1H, C_H), 1.92 (m, 2H, C_H), 1.57 (m, 1H, CγH), 0.91 (m, 6H, C_H); Nle5: _ 7.60 (br s, 1H, NH),
4.34 (m, 1H, C_H), 1.75 (m, 2H, C_H), 1.57 (m, 2H, CγH), 1.27 (m, 2H, C_H), 0.91 (m, 3H, C_H);
Gly6: _ 7.81 (bs, 1H, NH), 3.91-4.12 (dd, 2H, C_H); Bug7: _ 7.85 (d, 1H, NH), 4.60 (m, 1H, C_H),
3.78 (s, 3H, OCH3), 2.62-2.85 (m, 2H, C_H); ES-MS: calcd for C33H54N7O10: 708.4, found: m/z: [M +
H]+ 708.8, [M + Na]+ 730.6, [(M – C4H8) + H]
+ 652.8, [(M – C5H8O2) + H]
+ 608.8. HRMS: calcd for
C33H53N7O10Na: 730.37478. Found: 730.37516.
Boc-Bug-Gly-OH: Coupling was carried out as described in the general procedure solution phase
peptide synthesis. Boc-Bug-Gly-OEt: Yield 83% (155 mg); Rf(DCM/MeOH 95:5 v/v): 0.70; 
1H NMR
(CDCl3, 300 MHz) Bug: _ 5.40 (d, 1H, NH), 4.30 (m, 1H, C_H), 2.52-2.71 (m, 2H, C_H), _ 1.79 (t,
3H, C_H), _ 1.46 (s, 9H, CH3 Boc); Gly: _ 7.01 (m, 1H, NH), 4.06 (m, 2H, C_H), 4.21 (q, 2H,
OCH2CH3), 1.27 (t, 3H, OCH2CH3); ES-MS: calcd for C15H24N2O5Na: 335.2, found: m/z: [M + Na]
+
335.2, [M + Na + CH3CN]
+ 376.2, [(M – C5H8O2) + H]
+ 213.2. Boc-Bug-Gly-OH: Boc-Bug-Gly-OEt
(155 mg, 0.5 mmol) was dissolved in THF (5 mL) and the ethyl ester was saponified with 0.2N LiOH
(4 mL) during 45 min at 0oC. Then, THF was partially removed in vacuo and the aqueous solution was
acidified with 1N KHSO4 and subsequently extracted with EtOAc (3 × 10 mL). The combined EtOAc
layers were washed with brine (1 × 15 mL), dried (Na2SO4), filtered and concentrated in vacuo. Yield:
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141 mg (quant); Rf(DCM/MeOH 95:5 v/v): 0; 
1H NMR (CDCl3, 300 MHz) Bug: _ 5.60 (d, 1H, NH),
4.39 (m, 1H, C_H), 2.60-2.69 (m, 2H, C_H), 1.77 (t, 3H, C_H), 1.45 (s, 9H, CH3 Boc); Gly: _ 8.62 (br
s, 1H, OH), 7.28 (m, 1H, NH), 4.00-4,11 (m, 2H, C_H); ES-MS: calcd for C13H20N2O5Na: 306.1,
found: m/z: [M + Na]+ 307.2, [M + Na + ACN]+ 348.2.
Boc-Bug1-Ala2-Bug3-Bug4-Asn(Trt)5-Bug6-OMe 14: The peptide was synthesized manually on a 0.20
mmol scale on plain Argogel resin as described in the general procedures. The peptide was purified by
column chromatography (eluens: DCM/MeOH 97.5:2.5→95:5 v/v). Yield: 187 mg (99%); Rf 0.60
(DCM/MeOH 9:1 v/v); Rt 18.94 min; 
1H NMR (DMSO-d6, 500 MHz) Bug
1: _ 6.98 (d, 1H, NH), 4.06
(m, 1H, C_H), 2.38-2.70 (m, 2H, C_H), 1.69 (s, 3H, C_H), 1.39 (s, 9H, Boc); Ala2: _ 7.93 (d, 1H, NH),
4.32-4.42 (m, 1H, C_H), 1.21 (d, 3H, C_H); Bug3: _ 7.98 (d, 1H, NH), 4.32-4.42 (m, 1H, C_H), 2.38-
2.70 (m, 2H, C_H), 1.69 (s, 3H, C_H); Bug4: _ 8.16 (d, 1H, NH), 4.32-4.42 (m, 1H, C_H), 2.38-2.70
(m, 2H, C_H), 1.69 (s, 3H, C_H); Asn(Trt)5: _ 8.63 (m, 1H, _NH), _ 8.29 (d, 1H, _NH), 7.16-7.29 (m,
15H, arom Trt), 4.59 (m, 1H, C_H), 2.38-2.70 (m, 2H, C_H); Bug6: _ 8.02 (d, 1H, NH), 4.32-4.42 (m,
1H, C_H), 3.63 (s, 3H, OCH3), 2.38-2.70 (m, 2H, C_H), 2.16 (s, 3H, C_H). ES-MS: calcd for
C56H67N7O10: 996.5, found: m/z: [M + H]
+ 996.8, [M + Na]+ 1018.7.
Boc-Alg1-Ala2-Bug3-Alg4-Asn(Trt)5-Bug6-OMe 16: The peptide was synthesized manually on a 0.20
mmol scale on plain Argogel resin as described in the general procedures. The peptide was purified by
column chromatography (eluens: DCM/MeOH 97.5:2.5→95:5 v/v). Yield = 180.6 mg (93%). Rf 0.60
(DCM/MeOH 9:1 v/v); Rt = 18.86 min; 
1H NMR (DMSO-d6, 500 MHz) Alg
1: _ 6.86 (d, 1H, NH), 5.69
(m, 1H, CγH), 4.98-5.11 (m, 2H, C_H), 3.98 (m, 1H, C_H), 2.17-2.57 (m, 2H, C_H), 1.37 (s, 9H, Boc);
Ala2: _ 7.93 (d, 1H, NH), 4.33-4.40 (m, 1H, C_H), 1.21 (d, 3H, C_H); Bug3: _ 8.16 (d, 1H, NH), 4.33-
4.40 (m, 1H, C_H), 2.17-2.57 (m, 2H, C_H), 1.69 (s, 3H, C_H); Alg4: _ 7.76 (d, 1H, NH), 5.69 (m, 1H,
CγH), 4.98-5.11 (m, 2H, C_H), 4.33-4.40 (m, 1H, C_H), 2.17-2.57 (m, 2H, C_H); Asn(Trt)5: _ 8.60 (m,
1H, _NH), _ 8.30 (d, 1H, _NH), 7.16-7.27 (m, 15H, arom Trt), 4.63 (m, 1H, C_H), 2.62 (m, 2H, C_H);
Bug6: _ 8.11 (d, 1H, NH), 4.33-4.40 (m, 1H, C_H), 3.63 (s, 3H, OCH3), 2.17-2.57 (m, 2H, C_H), 2.16
(s, 3H, C_H). ES-MS: calcd for C54H66N7O10: 972.5, found: m/z: [M + H]
+ 972.7, [M + Na]+ 994.6.
Boc-Alg1-Ala2-cyclo(Bug3-Alg4-Asn(Trt)5-Bug6)-OMe 17: Linear hexapeptide 16 (44.3 mg, 0.05
mmol) was dissolved in toluene (200 mL) and the catalyst (3.9 mg, 8.3 _mol) was added. The obtained
mixture was heated to and stirred at 80oC for 90 min. The product was purified by column
chromatography (DCM/MeOH 97.5:2.5 v/v). Yield: 27.5 mg. This was a mixture of the desired product
and a side product in a ratio 3:2. These two products were seperated by preparative HPLC
chromatography to yield the desired product (4.6 mg) as jugded by MS/MS. Rf = 0.60 (DCM/MeOH
S11
9:1 v/v); R t 17.93 min; 
1H NMR (CDCl3, 500 MHz) Alg
1: _ 5.45 (bs, 1H, NH), 5.65-5.74 (m, 1H,
CγH), 5.06-5.15 (m, 2H, C_H), 4.14 (m, 1H, C_H), 2.38-2.64 (m, 2H, C_H), 1.43 (s, 9H, Boc); Ala2: _
7.41 (bs, 1H, NH), 4.42 (m, 1H, C_H), 1.37 (d, 3H, C_H); Bug3: _ 7.58 (bs, 1H, NH), 4.49 (m, 1H,
C_H), 2.38-2.64 (m, 2H, C_H); Alg4: _ 7.95 (bs, 1H, NH), 5.65-5.74 (m, 1H, CγH), 4.06-5.15 (m, 2H,
C_H), 4.22 (m, 1H, C_H), 2.65-2.74 (m, 2H, C_H); Asn(Trt)5: _ 7.58 (bs, 1H, _NH), _ 8.03 (d, 1H,
_NH), 7.18-7.28 (m, 15H, arom Trt), 4.62 (m, 1H, C_H), 2.78 (m, 2H, C_H); Bug6: _ 7.34 (d, 1H, NH),
4.73 (m, 1H, C_H), 3.79 (s, 3H, OCH3), 2.38-2.64 (m, 2H, C_H). ES-MS: calcd for C50H60N7O10:
918.4, found: m/z: [M + H]+ 918.7, [M + Na]+ 940.8.
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